New antifungal drug has been registered
Mirpharm reports about successful registration of a new antifungal drug - Anidulafungin
Moscow, December 2022
Mirpharm has successfully completed the registration of a new drug, Anidulafungin manufactured in Europe. Anidulafungin is an antifungal drug of systemic action and is a semi-synthetic echinocandin, a lipopeptide synthesized from the fermentation product of Aspergillus nidulans. It selectively inhibits 1,3-ß-D glycan synthetase, an important component of the cell wall of fungi. In mammalian cells 1,3-ß-D glycan synthetase is absent. Anidulafungin has been found to have fungicidal activity against Candida spp. and also suppresses cellular growth of Aspergillus fumigatus.
Production is located in Latvia, Olaine and is GMP certified.
Note:
The press release contains information on prescription drugs. Use of this information for preparation of publications must be made in accordance with the legislation of the Russian Federation on advertising (including but not limited to Art. 24 of the Federal Law of 13.03.2006 No. 38-FZ "On Advertising"), according to which, in particular, advertising of drugs available on prescription is allowed only in places of medical or pharmaceutical exhibitions, seminars, conferences and other similar events as well as in special places designed for medical and pharmaceutical workers. Failure to comply with the above requirements (namely, mentioning the name of the drug, placing an image of the package or its elements in the media other than specialized print publications intended for medical and pharmaceutical workers) shall entail administrative liability.